Laurus Labs Limited

NSE LAURUSLABS.NS

Laurus Labs Limited Revenue Per Share for the year ending March 31, 2024: USD 1.11

Laurus Labs Limited Revenue Per Share is USD 1.11 for the year ending March 31, 2024, a -18.56% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Laurus Labs Limited Revenue Per Share for the year ending March 31, 2023 was USD 1.37, a 13.96% change year over year.
  • Laurus Labs Limited Revenue Per Share for the year ending March 31, 2022 was USD 1.20, a -0.39% change year over year.
  • Laurus Labs Limited Revenue Per Share for the year ending March 31, 2021 was USD 1.20, a 75.45% change year over year.
  • Laurus Labs Limited Revenue Per Share for the year ending March 31, 2020 was USD 0.69, a 13.09% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
NSE: LAURUSLABS.NS

Laurus Labs Limited

CEO Dr. Satyanarayana Chava M.Sc., Ph.D.
IPO Date Dec. 19, 2016
Location India
Headquarters Serene Chambers
Employees 6,007
Sector Health Care
Industries
Description

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.

Similar companies

DEEPAKNTR.NS

Deepak Nitrite Limited

USD 27.05

0.71%

SYNGENE.NS

Syngene International Limited

USD 9.56

0.73%

IEX.NS

Indian Energy Exchange Limited

USD 1.93

3.86%

DIXON.NS

Dixon Technologies (India) Limited

USD 188.04

2.93%

DIVISLAB.NS

Divi's Laboratories Limited

USD 69.21

4.65%

StockViz Staff

January 15, 2025

Any question? Send us an email